锦欣生殖宣布未来三年股东回报规划:约占经调整EBITDA50%-80%

中金财经
Mar 26

  中国最大的试管婴儿医疗服务提供商锦欣生殖(1951.HK)3月26日发布公告称,参考其经调整自由现金流,将通过股息分派及股份回购等方式,启动为其三年的股东回报计划,实现总额相当于相关财政年度经调整EBITDA之50%至80%的股东总回报。分析人士认为,该股东回来方式“诚意满满”,显示了公司盈利能力的强大信心和长期主义。   本次股东回报计划除了诚意十足,回购机制也非常灵活,公告显示,当股价显著低于账面价值且未真实反映公司的内在价值或公司实际前景时,公司将优先启动场内回购,以维护股价并提升每股内在价值。   行业人士分析认为,这样大的股东回报显示了锦欣生殖稳健的财务支撑,由于深圳医院已完成搬迁,投产后的资本开支缩减,强大的自由现金流将为该规划提供坚实保障,标志着锦欣生殖进入了“业务稳健增长、资本高效回报”的新阶段。   

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10